PSMA Therapeutics

PSMA Therapeutics was a biotechnology company focused on the development of targeted therapeutics and imaging agents for prostate cancer, specifically leveraging the prostate-specific membrane antigen (PSMA) biomarker. The company was established as a joint venture between Progenics Pharmaceuticals and the Cornell Research Foundation to commercialize PSMA-targeting technology developed at Weill Cornell Medicine. Its portfolio included key assets such as 177Lu-PNT2002 and various PSMA-targeted imaging agents. Following the acquisition of Progenics by Lantheus Holdings, the company's assets and intellectual property were integrated into the Lantheus oncology pipeline, contributing to the commercial success of PSMA-targeted radiopharmaceuticals.